rtki cpd has been researched along with ag-490 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
| Arbel, R; Ben-Bassat, H; Hartzstark, Z; Klein, BY; Laufer, N; Levitzki, R; Rojansky, N | 1 |
| Dowlati, A; Kern, JA; Nethery, D | 1 |
| Halgunset, J; Larsson, E; Skogseth, H | 1 |
| Arany, I; Megyesi, JK; Nelkin, BD; Safirstein, RL | 1 |
7 other study(ies) available for rtki cpd and ag-490
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |
Inhibitors that target protein kinases for the treatment of ovarian carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Catechols; Cell Cycle; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Nitriles; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Time Factors; Tumor Cells, Cultured; Tyrphostins | 2003 |
Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy.
Topics: Antibodies, Monoclonal; Cell Division; Cell Line, Tumor; DNA-Binding Proteins; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Inhibitory Concentration 50; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor; Trans-Activators; Tyrphostins | 2004 |
Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Genistein; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Tyrphostins; Urokinase-Type Plasminogen Activator | 2005 |
STAT3 attenuates EGFR-mediated ERK activation and cell survival during oxidant stress in mouse proximal tubular cells.
Topics: Animals; Cell Line; Cell Survival; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Hydrogen Peroxide; Janus Kinase 2; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred Strains; Oxidative Stress; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Tyrosine; Tyrphostins | 2006 |